|
業務類別
|
Biotechnology |
|
業務概覽
|
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer andmetastatic castration-resistant prostate cancer, are ongoing. |
| 公司地址
| 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446 |
| 電話號碼
| +1 763 392-0767 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.celcuity.com |
| 員工數量
| 155 |
| Dr. Lance G. Laing |
Director, Chief Science Officer, Vice President and Secretary |
美元 472.56K |
02/04/2026 |
| Mr. Brian F. Sullivan |
Chairman of the Board and Chief Executive Officer |
美元 577.10K |
02/04/2026 |
| Ms. Vicky Hahne |
Chief Financial Officer and Principal Accounting Officer |
美元 419.60K |
02/04/2026 |
|
|
| Mr. Charles R. Romp |
Independent Director |
02/04/2026 |
| Dr. Polly A. Murphy, D.V.M.,PhD |
Independent Director |
02/04/2026 |
| Dr. Richard E. Buller, M.D.,PhD |
Independent Director |
02/04/2026 |
| Dr. Leo T. Furcht, M.D. |
Independent Director |
02/04/2026 |
| Dr. Lance G. Laing |
Director, Chief Science Officer, Vice President and Secretary |
02/04/2026 |
| Mr. Richard J. Nigon |
Independent Director |
02/04/2026 |
| Mr. David F. Dalvey |
Independent Director |
02/04/2026 |
| Mr. Brian F. Sullivan |
Chairman of the Board and Chief Executive Officer |
02/04/2026 |
|
|
|
|
